Beta Finch - S&P 100 - EN

# Beta Finch Podcast Script: Amazon Q1 2026 Earnings

**ALEX:** Welcome back to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you what really matters from corporate America's latest results. I'm Alex, and joining me as always is Jordan. Today we're diving into Amazon's blockbuster Q1 2026 earnings that just dropped, and folks, this was a quarter that reminded everyone why AMZN remains one of the most closely watched stocks in the market.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Jordan, Amazon just posted some absolutely staggering numbers. Walk us through the headline figures.

**JORDAN:** Alex, these results were genuinely impressive across the board. Amazon delivered $181.5 billion in revenue, up 17% year-over-year, or 15% excluding foreign exchange impacts. But here's the kicker - operating income hit $23.9 billion with a 13.1% operating margin. Andy Jassy specifically called this their highest operating margin ever.

**ALEX:** That margin number really jumps out. For a company of Amazon's scale to be hitting record profitability while still growing at this pace is remarkable. But the real story here seems to be AWS, right?

**JORDAN:** Absolutely. AWS was the star of the show. Revenue hit $37.6 billion with 28% year-over-year growth - that's the fastest growth rate AWS has seen in 15 quarters. And get this - Jassy said it's very unusual for a business to grow this fast on a $150 billion annualized run rate. The last time they saw growth at this clip, AWS was roughly half the size.

**ALEX:** The AI story is clearly driving a lot of this growth. What stood out to you from their AI commentary?

**JORDAN:** The AI numbers are just mind-blowing when you put them in context. Jassy mentioned that three years after AWS launched, it had a $58 million revenue run rate. But in the first three years of this AI wave, AWS's AI revenue run rate is over $15 billion - that's 260 times larger. He said they've never seen a technology grow as rapidly as AI.

**ALEX:** And they're not just riding the wave - they're building their own chips to compete. Tell us about their custom silicon story.

**JORDAN:** This might be the most underappreciated part of Amazon's business right now. Their chips business saw nearly 40% quarter-over-quarter growth, with an annual revenue run rate now over $20 billion. But here's the fascinating part - Jassy said if their chips business sold chips like other leading chip companies do, their annual revenue run rate would be $50 billion. He believes they're now one of the top three data center chip businesses in the world.

**ALEX:** That's incredible positioning, especially when you consider the supply constraints everyone's dealing with. Speaking of which, how are they handling the memory and component cost inflation that's hitting everyone right now?

**JORDAN:** Jassy was pretty candid about this challenge. He said component costs, particularly memory, have "skyrocketed" due to insufficient capacity for the demand. But interestingly, he sees this as actually helping AWS win more enterprise customers. Since cloud providers are getting priority from suppliers, companies with on-premises infrastructure are being pushed to migrate to the cloud faster because AWS has more supply than they can get on their own.

**ALEX:** That's a fascinating competitive dynamic. Now, outside of AWS, how did the core retail business perform?

**JORDAN:** The retail side showed impressive momentum too. Units grew 15% year-over-year - Jassy said that's the highest they've seen since the tail end of COVID lockdowns. Their grocery business is now generating more than $150 billion in gross sales, making them the second-largest grocer in the U.S.

This episode includes AI-generated content.

# Beta Finch Podcast Script - Visa Q2 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that matter. I'm Alex, and I'm here with my co-host Jordan to break down Visa's absolutely stellar Q2 2026 results. Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex, and wow - where do we even start with these numbers? Visa just delivered what CEO Ryan McInerney called "the strongest net revenue growth since 2022" - and when you exclude post-pandemic recovery periods, we're talking about the strongest growth since 2013!

**ALEX:** The headline numbers are just incredible. Net revenue jumped 17% year-over-year to $11.2 billion, and earnings per share grew 20%. But Jordan, what really caught my attention was how broad-based this strength was across all their business segments.

**JORDAN:** Absolutely. Let's break this down for our listeners. Payments volume grew 9% to $3.7 trillion - that's trillion with a T - and they processed 66 billion transactions, also up 9%. But here's what's really interesting: their Value-Added Services business, which is becoming a huge growth driver, jumped 27% and now represents 30% of their total revenue.

**ALEX:** That VAS number is crucial because it shows Visa isn't just a traditional payments processor anymore. They're becoming this comprehensive financial technology platform. Ryan McInerney spent a lot of time talking about four key growth drivers, and AI-powered "agentic commerce" was front and center.

**JORDAN:** Right, and I have to admit, some of this agentic commerce stuff sounds pretty futuristic. Essentially, they're betting that AI agents - think ChatGPT but for shopping - will create entirely new categories of transactions. These agents might split purchases across multiple transactions to optimize pricing, or even pay for their own data consumption transaction by transaction.

**ALEX:** It sounds wild, but McInerney made a compelling case. He said agents will prefer to use Visa cards because they offer privacy, broad acceptance, built-in security protections, and rewards. Plus, Visa already has 5 billion credentials across 200 countries - that's a massive head start.

**JORDAN:** The stablecoin strategy was equally fascinating. They're positioning themselves as what McInerney called a "hyperscaling bridge layer" between cryptocurrency infrastructure and real-world applications. They now have over 160 stablecoin card programs globally, and that payment volume grew nearly 200% year-over-year.

**ALEX:** And get this - they're settling $7 billion annually in stablecoins with their financial partners, up more than 50% just since last quarter. They've added five new blockchains for settlement, bringing their total to nine. This isn't some distant future play - it's happening right now.

**JORDAN:** Let's talk about that Wells Fargo announcement because that was a huge validation of their Pismo acquisition. Wells Fargo is migrating to Pismo's core account ledger as part of their banking modernization. When you can land one of the biggest banks in the US, that's a pretty strong signal about your technology.

**ALEX:** CFO Chris Suh was really bullish about their guidance too. They raised their full-year net revenue growth outlook to "low double-digit to low teens" - and they specifically mentioned increased client enthusiasm around the FIFA World Cup driving higher value-added services revenue.

**JORDAN:** The FIFA example he gave was incredible. They partnered with one client in Latin America with nearly 20 million cards for FIFA campaigns. In just over three months, that client saw a 10% lift in active cards, and Visa generated $10 million in VAS revenue. That's th

This episode includes AI-generated content.

# Beta Finch Podcast Script: Mondelez Q1 2026 Earnings

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we decode the numbers that move markets. I'm Alex, and joining me as always is Jordan. Today we're diving into Mondelez International's Q1 2026 results - and folks, this one's got some interesting twists.

Now, before we get into the snack food giant's performance, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And what a quarter this was for Mondelez. Right off the bat, we're seeing some really compelling geographic dynamics here. Emerging markets absolutely crushed it with 6.3% growth, while developed markets are showing signs of recovery after some challenging periods.

**ALEX**: That's right. And Jordan, I think what stood out to me most was CEO Dirk Van de Put's commentary about the consumer landscape. It's this tale of two worlds - you've got emerging markets like India showing double-digit growth, but then you have this underlying fragility everywhere due to Middle East tensions affecting energy and commodity costs.

**JORDAN**: Exactly. And let's talk numbers for a second. That emerging markets growth of 6.3% is really broad-based. India was particularly strong with double-digit growth in both chocolate and biscuits. They even launched Biscoff in India and the line is already sold out - that's the kind of execution you want to see.

**ALEX**: Speaking of Biscoff, this partnership keeps coming up as a major growth driver. Van de Put seemed genuinely excited about it, calling it something that will be "really quite big for them and for us in the coming years." They're not just doing biscuits - they're incorporating Biscoff cream and crumbs into their chocolate products too.

**JORDAN**: And that innovation strategy is fascinating. They're making what Van de Put called "bigger and fewer bets." Instead of throwing everything at the wall, they're focusing on four key areas: well-being products with protein and fiber, premium chocolate, the Biscoff partnership, and cakes and pastries through acquisitions and brand extensions.

**ALEX**: Now, here's where it gets interesting from a financial perspective. CFO Luca Zaramella said they're ahead of expectations in Q1, but they're maintaining their EPS guidance for 2026. Why? Because they're facing unexpected headwinds from the Middle East situation - extra costs for alternative supply routes, higher oil prices affecting some regulated markets.

**JORDAN**: Right, and this is where management's capital allocation philosophy really shows. Zaramella was pretty clear - if they do see EPS upside materializing, they're going to invest it back into the business rather than just dropping it to the bottom line. They're playing the long game here, especially with their commitment to "strong 2027 EPS growth."

**ALEX**: Let's talk about Europe for a moment, because this was a real bright spot. They completed most of their retail negotiations ahead of Easter, saw market share gains, and had what Van de Put called a "very robust Easter season." The Biscoff partnership is performing particularly well in Australia and New Zealand too.

**JORDAN**: And the competitive dynamics in Europe around chocolate pricing seem to have stabilized. Remember, there were big concerns about cocoa price volatility and how that might trigger a pricing war. But Van de Put said customer negotiations went well, and they're not seeing any major price movements right now. The industry seems to be waiting to see what the main crop brings.

**ALEX**: The U.S. market is more challenging though. Van de Put was pretty candid about consumer confidence remaining low, with expectations it could deteriorate further. But here's the thing - they're

This episode includes AI-generated content.

# Beta Finch Podcast Script: Regeneron Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're breaking down Regeneron's first quarter 2026 results, and folks, this biotech giant is firing on all cylinders.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Absolutely. Now Alex, let's talk numbers because Regeneron just posted some impressive results. Revenue jumped 19% to $3.6 billion, and non-GAAP earnings per share grew 15%. Those are solid double-digit growth numbers across the board.

**ALEX:** What really caught my attention is the DUPIXENT story. This drug is becoming an absolute juggernaut - global net sales hit $4.9 billion in the quarter, up 31% on a constant currency basis. Jordan, we're looking at annualized sales approaching $20 billion for this single drug.

**JORDAN:** It's incredible when you put it in perspective. DUPIXENT is now treating over 1.4 million patients worldwide, and they keep expanding into new indications. This quarter alone, they got approval for allergic fungal rhinosinusitis and chronic spontaneous urticaria in younger patients. It's like they're building a franchise within a franchise.

**ALEX:** Speaking of franchises, let's talk about their eye drug portfolio. EYLEA HD had a strong quarter with U.S. sales of $468 million, up 52% year-over-year. But here's the interesting dynamic - while EYLEA HD is growing rapidly, the original EYLEA is declining as expected, down 36%. It's a classic product transition story.

**JORDAN:** And there's still some uncertainty hanging over that transition. They're waiting on FDA approval for the EYLEA HD prefilled syringe, which missed its April deadline. Management expects a decision this quarter, but it shows how regulatory timing can impact even established companies like Regeneron.

**ALEX:** Now, what really excited me during the call was the pipeline discussion. CEO Leonard Schleifer and Chief Scientific Officer George Yancopoulos laid out some compelling near-term catalysts. They've got this complement inhibitor cemdisiran for myasthenia gravis that showed really impressive Phase 3 results.

**JORDAN:** The data on that was striking. Their drug delivered a 2.3-point improvement compared to placebo, which actually outperformed existing treatments that showed 1.6 to 1.9 points in their trials. Plus, it's dosed quarterly versus every two weeks for competitors. That convenience factor could be huge.

**ALEX:** And then there's their obesity play with olatorepatide. This is where Regeneron is trying to differentiate in the crowded GLP-1 space. Their strategy is fascinating - they want to combine this obesity drug with their cholesterol drug Praluent.

**JORDAN:** George Yancopoulos made a compelling pitch on this during the Q&A. He basically said, imagine you have a GLP-1 that works as well as the best ones out there, but also lowers your bad cholesterol by 50% and reduces cardiovascular risk. Why would anyone choose a different GLP-1? It's an interesting value proposition in a competitive market.

**ALEX:** What struck me about that answer is how confident they sounded. Yancopoulos said it would be a "no-brainer" choice for physicians and patients. That's either brilliant positioning or they're setting themselves up for disappointment. Time will tell.

**JORDAN:** One moment that really stood out was when they announced they're giving away their new gene therapy, Otarmeni, for free in the U.S. This treats genetic hearing loss in children, and they got FDA approval just last week.

**ALEX:** That was such an interesting strategic decision. Schleifer said they'r

This episode includes AI-generated content.

# Beta Finch Podcast Script: AbbVie Q1 2026 Earnings

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into AbbVie's first quarter 2026 results.

**JORDAN**: Hey everyone! Before we jump in, we need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**ALEX**: Absolutely. Now Jordan, AbbVie just delivered what I'd call a knockout quarter. They beat expectations across the board and raised guidance - what stood out to you first?

**JORDAN**: The numbers are impressive, Alex. They hit $2.65 in adjusted earnings per share, which was 7 cents above their guidance midpoint. But what really caught my eye was that revenue growth - 12.4% to $15 billion, beating expectations by $300 million. That's some serious momentum.

**ALEX**: And they're not just celebrating - they're doubling down. They raised their full-year EPS guidance by 12 cents to between $14.08 and $14.28. What's driving this confidence?

**JORDAN**: Two words: Skyrizi and immunology. Skyrizi alone pulled in $4.5 billion in sales, up over 29% operationally. CEO Robert Michael specifically called out the "momentum in immunology and neuroscience" with both segments gaining market share in growing markets. This isn't just about riding a wave - they're creating it.

**ALEX**: The Skyrizi story is fascinating because it shows how a well-positioned drug can dominate even in a competitive landscape. Jeff Stewart, their commercial head, mentioned they have "over 4x basically the in-play share" versus their next competitor. How sustainable is that kind of dominance?

**JORDAN**: That's the million-dollar question, Alex. They're facing new competition, including an oral competitor that launched recently. But Stewart seemed pretty confident during the Q&A, pointing to their head-to-head trials across five different mechanisms in psoriasis, superior durability data, and that convenient quarterly dosing. He even suggested the oral competition might expand the market rather than just steal share.

**ALEX**: Speaking of competition, one analyst specifically asked about competitive pressure, and I found Stewart's response really telling. He basically said their audit data shows NBRx - new prescriptions - hitting all-time highs despite having incredibly high market share already. That suggests real physician preference, not just early adoption.

**JORDAN**: Exactly. And they're not just defending Skyrizi - they're expanding it. The subcutaneous induction data for Crohn's disease looked impressive. Dr. Roopal Thakkar highlighted that in treatment-naive patients, 61% achieved endoscopic response and 73% achieved clinical remission. Those are some serious numbers.

**ALEX**: But here's where it gets really interesting - their combination strategy. Tell our listeners about this Skyrizi plus alpha-4 beta-7 antibody data.

**JORDAN**: This is potentially game-changing, Alex. In their platform study, the combination doubled the endoscopic remission rate compared to either drug alone - about 42% of patients at week 24. And remember, this was in severely refractory patients where 82% had failed advanced treatments. Thakkar called it "potentially transformative efficacy."

**ALEX**: The R&D pipeline seems to be the real story here. They're not just maintaining current success - they're building the next generation. What else caught your attention?

**JORDAN**: Their obesity program is heating up. The early data on ABBV-295, their long-acting amylin analog, showed nearly 10% weight loss in just 12 weeks. In a predominantly male, non-obese population, no less. With a 270-hour half-life, they're talking about potential monthly dosing, which could be huge for patient compliance.

**ALEX**: And let's not forget neu

This episode includes AI-generated content.

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown, bringing you the latest insights from corporate America's quarterly results. I'm Alex, and I'm joined by my co-host Jordan. Today we're diving into T-Mobile's Q1 2026 earnings call, and folks, this was quite a performance from the Un-carrier.

Before we get started, I need to share an important disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN**: Thanks Alex. And wow, T-Mobile really came out swinging this quarter. Let's start with the headline numbers because they're pretty impressive. Service revenue grew 11% year-over-year - that's four times faster than their closest competitor. But what really caught my eye was their customer satisfaction score, or NPS, hitting 45 - that's over 20% higher than their nearest rival.

**ALEX**: That NPS number is huge, Jordan. It really speaks to their strategy of providing "best network, best value, and best experience" all in one package. CEO Srinivasan Gopalan kept hammering this point that customers don't need to make trade-offs anymore with T-Mobile. And the numbers back it up - they added 217,000 postpaid net accounts, up 6% year-over-year, while also growing their average revenue per account by 3.9%.

**JORDAN**: Exactly. That's the holy grail - growing both customer volume AND revenue per customer. Speaking of growth, their broadband business continues to be a monster. They added over 500,000 broadband customers this quarter and called themselves "the fastest-growing ISP in America" yet again. They're targeting 15 million broadband customers by 2030, and here's the kicker - that projection assumes they don't buy any more spectrum and doesn't factor in 6G improvements.

**ALEX**: The broadband story is fascinating because they're using what they call "fallow capacity" on their 5G network. Essentially, they've built this massive network infrastructure, and during off-peak times, they can sell that unused capacity as home internet service. It's brilliant from a capital efficiency standpoint.

But Jordan, I think the most intriguing part of this call was their discussion about AI and what they're calling "physical AI." They announced a partnership with Figure AI to connect humanoid robots to their 5G Advanced network.

**JORDAN**: This is where things get really futuristic, Alex. T-Mobile is positioning itself at the intersection of AI and connectivity. They talked about building AI capabilities directly into their network core, and they're already beta-testing something called "Live Translation" that can translate your voice into 80 different languages in real-time. But the physical AI angle is what has me excited - they see a world where their network becomes the backbone for robotics and automation.

**ALEX**: The key insight from network chief John Saw was that T-Mobile built their 5G Advanced network specifically with this future in mind. They have innovations like uplink transmit switching and higher transmit power that give them advantages for these AI applications. It's not just about faster phones - they're thinking about robots, autonomous systems, and edge computing.

**JORDAN**: And that brings us to their guidance updates. CFO Peter Osvaldik raised several key metrics. They're now expecting 950,000 to 1.05 million total postpaid net account additions for the full year, up from previous guidance. Core adjusted EBITDA guidance went up by $100 million at the low end to $37.1-37.5 billion. Free cash flow guidance also increased by $100 million to $18.1-18.7 billion.

**ALEX**: Those guidance raises show real confidence in the business momentum. But what really caught investors' attention was the announcement that they're increasing their shareholder return authorization by $3.6 billion to

This episode includes AI-generated content.

# Beta Finch Podcast Script: Starbucks Q2 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into Starbucks' second quarter 2026 results, and folks, this is a story about a turnaround that's actually working.

**ALEX:** Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Right, and what a quarter to analyze! Starbucks just delivered something they haven't done in over two years - simultaneous top and bottom line growth.

**ALEX:** The numbers are pretty impressive. Revenue hit $9.5 billion, up 9% year-over-year. But Jordan, what really caught my attention was that earnings per share jump - $0.50, up 22% from last year.

**JORDAN:** Exactly! And CEO Brian Niccol was clearly excited about this milestone. He called it "a turn in our turnaround," which is quite the statement. The global comparable sales growth of 6% was driven by what he described as "terrific performance across the business, especially in the U.S."

**ALEX:** Let's break down those U.S. numbers because they're really telling. U.S. comps accelerated to over 7%, with more than 4 percentage points coming from transaction growth. Niccol mentioned they haven't seen this kind of transaction strength in three years.

**JORDAN:** That transaction growth is huge, Alex. It means people are actually visiting more, not just spending more per visit. And here's what's fascinating - they're seeing broad-based growth across all income levels and age demographics. In this economic environment, that's remarkable.

**ALEX:** Speaking of remarkable, let's talk about their "Back to Starbucks" strategy. Niccol really emphasized their "Green Apron Service" model. Jordan, can you explain what they're tracking here?

**JORDAN:** Sure! They use something called a "Grow scorecard" that tracks customer comments, throughput, staffing, and food safety. They measure stores on a 5-shot system, and since launching this in October, they've seen over a 30 percentage point increase in stores delivering 4 or more shots. But here's the kicker - about 40% of stores still aren't at that 4-shot level, so there's room to grow.

**ALEX:** That's a great operational insight. And internationally, all top 10 markets, including China, posted positive comparable sales for the first time in 9 quarters. Though there's a big strategic shift happening with China, isn't there?

**JORDAN:** Absolutely. They completed their transaction with Boyu Capital, transitioning China to a joint venture model. CFO Catherine Smith mentioned this deal is valued at more than $13 billion, and Starbucks received about $3.1 billion in cash proceeds. Starting in Q3, China will be deconsolidated from their financials.

**ALEX:** Now let's talk guidance, because management got pretty confident here. They raised their global comparable sales growth guidance to "5% or better" and boosted their EPS range to $2.25 to $2.45.

**JORDAN:** Right, and when analysts pressed on why the EPS raise wasn't even higher given the strong performance, Smith was candid about macro headwinds. She mentioned elevated coffee prices - almost a dollar per pound year-over-year - and tariff impacts, though both are expected to moderate in the back half of the year.

**ALEX:** One thing that jumped out in the Q&A was the discussion about their rewards program. They just redesigned it in March, and typically that causes some disruption. But Niccol said membership actually grew, which is unusual for that quarter.

**JORDAN:** That's impressive execution. The new program has three tiers - green, gold, and reserve - and they introduced a popular 60-star redemption option that accounts for about a third of al

This episode includes AI-generated content.

# Beta Finch Podcast Script: Booking Holdings Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we dive deep into the numbers that move markets. I'm Alex, and I'm joined as always by my co-host Jordan. Today we're unpacking Booking Holdings' Q1 2026 results - and folks, this one's got some interesting twists.

Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Thanks Alex. And what a quarter this was for Booking. On the surface, the numbers look solid - revenue up 16% to $5.5 billion, adjusted EBITDA growing 19% to about $1.3 billion. But dig deeper and there's a significant geopolitical shadow hanging over these results.

**ALEX:** Absolutely. The Middle East conflict that started in late February really threw a wrench into what could have been an even stronger quarter. CEO Glenn Fogel estimated it knocked about 2 percentage points off their room night growth. Without that impact, their 6% room night growth would have been closer to 8%.

**JORDAN:** That's a meaningful difference, Alex. And what struck me was how transparent management was about the impact. CFO Ewout Steenbergen broke it down pretty clearly - the Middle East represents about 4% of their global room nights from bookers in the region, but when you include inbound travel, it's about 7% of their total 2025 room nights. So this isn't a small market for them.

**ALEX:** Right, and the ripple effects went beyond just the Middle East itself. They saw impacts on major transit corridors, particularly between Europe and Asia, since places like Dubai are huge connection hubs. March was especially brutal with room night growth of just 1% - half from reduced bookings, half from increased cancellations.

**JORDAN:** But here's what I found encouraging - despite all this disruption, they still beat the high end of their guidance on adjusted EBITDA. And Glenn Fogel's commentary was pretty reassuring about their long-term view. He pointed out they've navigated crises before - 9/11, the financial crisis, COVID, Russia-Ukraine. The fundamental desire for travel doesn't disappear.

**ALEX:** Speaking of things that don't disappear - their capital allocation strategy. Jordan, they returned a record $3.6 billion in share buybacks this quarter alone. Since 2014, they've reduced their share count by over 40% at an average price of $93 per share. That's some serious confidence in their long-term value.

**JORDAN:** It really is. And you know what caught my attention? The U.S. performance. This was their fourth consecutive quarter of acceleration in the U.S., hitting low teens growth in room nights. That's impressive market share gains in what Glenn called a market where they "have room to grow."

**ALEX:** The U.S. story is fascinating because it shows their strategy working. They've been talking for years about investing in the U.S. market - better products, brand awareness, supply relationships. And now we're seeing it pay off with domestic travel driving that growth and their direct channel seeing double-digit growth.

**JORDAN:** And they're not just winning in accommodations. Their "Connected Trip" vision is gaining real traction. Flights were up 28%, attractions up 25%. Connected transactions - where travelers book multiple verticals with them - grew at a high teens rate, about 3x faster than their total transaction growth.

**ALEX:** Let's talk AI for a moment because that was a major theme. Their Priceline AI assistant Penny is showing some promising early results. In limited testing, they're seeing conversion rate improvements from users who engage with Penny versus those who don't.

**JORDAN:** The AI investments seem comprehensive too. It's not just customer-facing stuff like Pe

This episode includes AI-generated content.

# Beta Finch Podcast Script - UPS Q1 2026 Earnings

**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn corporate calls into conversations you can actually follow. I'm Alex.

**JORDAN:** And I'm Jordan. Today we're diving into UPS's first quarter 2026 results, and wow - this was one packed earnings call.

**ALEX:** Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Right, thanks Alex. So UPS - the brown trucks we all know - just reported Q1 numbers, and there's a lot to unpack here. They're in the middle of what CEO Carol Tomé calls "the largest driver reduction in company history."

**ALEX:** That's quite a statement. Let's start with the numbers though. Revenue came in at $21.2 billion, operating profit was $1.3 billion, and operating margin hit 6.2%. But Jordan, the real story here isn't just the numbers - it's this massive strategic transformation they're executing.

**JORDAN:** Absolutely. The elephant in the room is Amazon. UPS has been deliberately reducing their Amazon business - they call it the "Amazon glidedown" - and they're almost done. Amazon now represents just 8.8% of total revenue, down from over 13% not too long ago.

**ALEX:** I found it fascinating how Carol Tomé framed this. She said they're "overturning the old industry assumption that scale alone drives profitability." Instead, they're focusing on premium segments like small and medium businesses, B2B customers, and healthcare.

**JORDAN:** And that strategy seems to be working. Their revenue per piece grew 6.5% year-over-year in the US, even as total volume dropped 8%. That's a classic example of making less revenue worth more profit.

**ALEX:** Speaking of healthcare - this was a standout. UPS generated over $3 billion in healthcare revenue for the first time ever in a single quarter. Jordan, why is this so significant?

**JORDAN:** Healthcare logistics is a premium business with higher margins. Think about it - if you're shipping temperature-sensitive medicines or medical devices, you need specialized handling, tracking, and delivery. You pay more for that reliability. Carol mentioned they're seeing opportunities with pharmaceutical companies going direct-to-consumer, especially with those GLP-1 diabetes and weight-loss drugs.

**ALEX:** The international segment was interesting too. Despite all the geopolitical challenges - trade wars, Middle East conflicts affecting airspace - they actually outperformed expectations. Revenue grew 3.8% to $4.5 billion.

**JORDAN:** That's impressive given the headwinds. Their China-to-US trade lane, which is their most profitable international route, was still down 18.3%. But here's the key insight from the call: trade doesn't stop, it just moves. They're seeing volume growth in other parts of the world as supply chains adapt.

**ALEX:** Now let's talk about the controversial part - this "Driver Choice" buyout program. They offered voluntary buyouts to reduce about 7,500 full-time driver positions, and it was apparently oversubscribed.

**JORDAN:** This is where the human element of these corporate transformations really hits home. UPS says they needed to right-size their workforce for the new volume levels after the Amazon reduction. The program was oversubscribed, meaning more drivers wanted to take the buyout than UPS could accept.

**ALEX:** The financial impact is significant. CFO Brian Dykes mentioned about $350 million in transitional costs in Q1, including this driver program, aircraft lease expenses, and weather-related costs. But they expect these costs to largely disappear in Q2.

**JORDAN:** Which brings us to guidance. They're sticking with their full-year targets: $89.7 billion in revenue and a 9.6% operating margin. Bu

This episode includes AI-generated content.

**BETA FINCH PODCAST SCRIPT**

---

**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, and I'm here with my co-host Jordan to dive into S&P Global's first quarter 2026 results. This one's particularly interesting given the backdrop of geopolitical tensions and the company's aggressive AI push.

Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

Jordan, S&P Global just reported some pretty solid numbers despite what CEO Martina Cheung called an "incredibly volatile and dynamic operating environment." Walk us through the headline numbers.

**JORDAN**: Absolutely, Alex. These results really showcase the resilience of S&P Global's business model. They posted 10% revenue growth year-over-year, with 9% organic constant currency growth. What really caught my eye was the 14% jump in adjusted diluted EPS and 140 basis points of margin expansion on a trailing twelve-month basis. That's impressive operating leverage.

**ALEX**: And they returned a billion dollars to shareholders through share repurchases alone, on top of dividends. But let's talk about the elephant in the room - this Iranian conflict that's been disrupting energy markets. How did that impact their different divisions?

**JORDAN**: Great question. The conflict created this interesting tale of two cities within S&P Global. On one hand, their Energy division faced direct headwinds - they actually lowered their full-year guidance for that segment by a full percentage point to 4.5% to 6% organic growth. CEO Cheung mentioned that some Middle Eastern energy customers had facilities directly impacted, and supply chain disruptions are expected to persist through the second quarter.

But here's what's fascinating - this volatility actually benefited other parts of the business. Their Ratings division saw 13% revenue growth, partly driven by what they called "hyperscaler" issuance - basically big tech companies issuing debt for AI infrastructure investments.

**ALEX**: That's a perfect segue into what I think is the real story here - S&P Global's AI transformation. Jordan, they're not just talking about using AI internally; they're fundamentally changing how customers access their data. Can you break down this strategy?

**JORDAN**: This is where it gets really interesting, Alex. S&P Global is essentially becoming an AI-native data company. They're making their data accessible through what they call "model context protocol" - basically allowing customers to use S&P data directly within AI platforms like Claude and ChatGPT.

The numbers they shared are eye-popping. API call volumes were 5x higher in Q1 versus just one quarter earlier, and doubled month-over-month from February to March alone. They now have over 300 customers either contracted or in trial periods for their AI-ready APIs.

**ALEX**: And they're seeing real pricing power from this AI integration, right?

**JORDAN**: Exactly. This is where the monetization story gets compelling. During the quarter, two financial clients opted to pay 35% to 45% premium increases just to get their data in AI-ready formats. CFO Eric Aboaf mentioned that customers using their AI solutions are showing much higher growth rates - 30% higher in Market Intelligence and double the growth rate in Energy compared to non-AI customers.

One example really stood out to me: they had a buy-side client working with their Kensho AI team who liked their AI plugin so much that they canceled their existing provider and switched to S&P Global, even though it was 20% more expensive.

**ALEX**: Let's talk about the guidance. They maintained most of their full-year outlook despite the geopolitical headwinds. What should investors expect for the rest of 2026?

**JORDAN**: S&P Global is sti

This episode includes AI-generated content.